Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
2132 results about "Tumor growth" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tumor growth rates are approximately exponential which means that the rate of growth depends on developmental stage 8. Tumor growth is exponential, as seen in the exponential, Gompertz and universal law models.
Apparatus and method for optimizing tumor treatment efficiency by electric fields
InactiveUS7146210B2Optimize spaceOptimal temporal characteristicSurgical instruments for heatingExternal electrodesElectricityCompanion animal
The apparatus and method are designed to compute the optimal spatial and temporal characteristics for combating tumor growth within a body on the basis of cytological (as provided by biopsies, etc.) and anatomical data (as provided by CT, MRI, PET, etc.), as well as the electric properties of the different elements. On the basis of this computation, the apparatus applies the fields that have maximal effect on the tumor and minimal effect on all other tissues by adjusting both the field generator output characteristics and by optimal positioning of the insulated electrodes or isolects on the patient's body.
Owner:NOVOCURE GMBH
Rho-kinase inhibitors
Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
Owner:BAYER HEALTHCARE LLC
Isolation and use of solid tumor stem cells
InactiveUS6984522B2Improved anti-cancer drug discoveryPromote resultsAnimal cellsMicrobiological testing/measurementAbnormal tissue growthCancer therapy
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Owner:RGT UNIV OF MICHIGAN
Variant annotation, analysis and selection tool
Disclosed are methods for detecting and / or prioritizing phenotype-causing genomic variants and related software tools. The methods include genomic feature based analysis and can combine variant frequency information with sequence characteristics such as amino acid substation. The methods disclosed are useful in any genomics study; for example, rare and common disease gene discovery, tumor growth mutation detection, personalized medicine, agricultural analysis, and centennial analysis.
Owner:UNIV OF UTAH RES FOUND +1
Methods for treating restenosis with p21
InactiveUS6218372B1Treating and preventing restenosis in vivoFacilitate immune recognitionBiocidePeptide/protein ingredientsPercent Diameter StenosisGene product
The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G0 / G1, alteration in morphology, and cell differentiation.
Owner:RGT UNIV OF MICHIGAN
Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor
InactiveUS6017898AEffective treatmentSugar derivativesPeptide/protein ingredientsDiseaseLymphatic Spread
Oligonucleotides are provided which are effective in inhibiting the growth, metastasis and / or angiogenesis of tumors, including particularly melanoma and / or lung cancer. Methods are also provided for use of these oligonucleotides in the treatment of diseases.
Owner:ICN PHARMA INC
Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
InactiveUS20070087001A1Inhibit or eliminate tumor metastasisPrevent tumors from metastasizingSenses disorderPeptide/protein ingredientsAbnormal tissue growthLymphatic Spread
The present invention concerns methods and compositions for inhibiting angiogenesis and / or tumor growth, survival and / or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and / or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
Owner:CENT FOR MOLECULAR BIOLOGY & MEDICINE +1
Historical comparison of breast tissue by image processing
An image processing system and method visually documents and displays changes between historical and later mammographic images, preferably in three dimensions. A composite image is created which visually emphasizes temporal differences between the historical and later images. Preferably three-dimensional, digitized images, displayable in various projections, are stored for archival purposes on computer readable media. An image processor preferably exploits an optical correlator to register the historical and later images accurately and provide correlation values as temporal scalars of the differences. The registered images are then compared, voxel-by-voxel, to detect temporal differences. The composite image is displayed with synthetic colors or other visual clues to emphasize apparent changes (for example, tumor growth or shrinkage).
Owner:LITTON SYST INC +1
Tr3-specific binding agents and methods for their use
InactiveUS6994976B1Prevent proliferationPeptide/protein ingredientsAntibody ingredientsAutoimmune responsesActive agent
Biologically active TR3-specific binding agents and methods for their use are disclosed. The biologically active TR3-specific binding agents are useful for inhibiting the proliferation of cells expressing TR3. These biologically active agents are particularly useful for treating T-cell mediated diseases such as graft-versus-host disease, organ rejection, tumor growth, autoimmunity, and inflammation.
Owner:TITTLE THOMAS V +1
(5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
The present invention relates to compounds having the formula I: which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Tumor suppression using placental stem cells
ActiveUS20080152624A1Promote formationPromote more developedBiocideGenetically modified cellsAbnormal tissue growthPlacental cell
The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell populations.
Owner:CELULARITY INC
Apparatus and method for statistical image analysis
An apparatus, system, method, and computer readable medium containing computer-executable code for implementing image analysis uses multivariate statistical analysis of sample images, and allows segmentation of the image into different groups or classes, depending on a correlation to one or more sample textures, or sample surface features. In one embodiment, the invention performs multivariate statistical analysis of ultrasound images, wherein a tumor may be characterized by segmenting viable tissue from necrotic tissue, allowing for more detailed in vivo analysis of tumor growth beyond simple dimensional measurements or univariate statistical analysis. Application of the apparatus and method may also be used for characterizing other types of samples having textured features including, for example, tumor angiogenesis biomarkers from Power Doppler.
Owner:PFIZER INC
Tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Human antibodies specific to KDR and uses thereof
The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.
Owner:IMCLONE SYSTEMS
Antibodies specific to KDR and uses thereof
InactiveUS20050214860A1Inhibit tumor growthCompound screeningVirusesSingle-Chain AntibodiesAngiogenesis growth factor
The invention provides an immunoglobulin molecule which binds KDR with an affinity comparable to human VEGF, and that neutralizes activation of KDR. Immunoglobulin molecules include monovalent single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, antibodies, humanized antibodies and chimerized antibodies. The invention further provides nucleic acid molecules that encode these immunoglobulin molecules. The invention also provides a method of making the immunoglobulin molecules mentioned above. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal with such immunoglobulin molecules.
Owner:ZHU ZHENPING +1
Compositions and methods of treating disease with FGFR fusion proteins
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
Owner:FIVE PRIME THERAPEUTICS
Compositions enriched in neoplastic stem cells and methods comprising same
A neoplastic stem cell population enriched for expression of the OCT4 transcription factor as well as methods for their identification, isolation and enrichment are described. The OCT4-enriched neoplastic stem cell population is further utilized for the induction and analysis of cancer in an animal. In addition, methods of preventing, abrogating, or inhibiting cancer, tumor growth, and metastasis via OCT4 inhibition are further provided.
Owner:UNIV OF TENNESSEE RES FOUND
Anti-tumor agents
InactiveUS6890904B1Prevent proliferationMinimize potentialDipeptide ingredientsTetrapeptide ingredientsAbnormal tissue growthLymphatic Spread
A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
Owner:DARA BIOSCI
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
InactiveUS6953855B2Modulate activityWithout side effectAntibacterial agentsBiocideDiseaseThiocarbamate
The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
Owner:ATTENUA INC
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00001.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00002.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00003.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
Owner:MERCK SHARP & DOHME CORP
Compounds and methods for treatment of cancer
ActiveUS20070004627A1Reduce tumor volumeInhibit tumor growthBiocidePeptide/protein ingredientsLymphatic SpreadImproved survival
The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.
Owner:FIBROGEN INC
Use of Anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ActiveUS20100166744A1Slow tumor growthReducing and inhibiting growth of tumorAntibody ingredientsImmunoglobulinsDiseaseTyrosine-kinase inhibitor
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies. Methods for treatment of cancer and reduction of tumor growth in individuals with secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy are provided. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies. Methods for treatment of recurrent lung cancer, including non-small cell lung carcinoma which is resistant to tyrosine kinase inhibitors, with the antibody anti-EGFR mAb806 are described.
Owner:DANA FARBER CANCER INST INC
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
InactiveUS20040057950A1Inhibit tumor growthPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthHuman tumor
Owner:WAKSAL HARLAN W +3
Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy
InactiveUS20110070156A1Organic active ingredientsHybrid immunoglobulinsParanasal Sinus CarcinomaAntiendomysial antibodies
Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.
Owner:IMMUNOMEDICS INC
Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
InactiveUS7642239B2Inhibit or eliminate tumor metastasisPrevent tumors from metastasizingSenses disorderPeptide/protein ingredientsLymphatic SpreadImmunotherapeutic agent
Owner:CENT FOR MOLECULAR BIOLOGY & MEDICINE +1
Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
InactiveUS20070021365A1Good curative effectInhibit biological activityCompound screeningApoptosis detectionAbnormal tissue growthCancer research
Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ActiveUS7723477B2Peptide/protein ingredientsAntibody mimetics/scaffoldsReceptorExtracellular Structure
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
Owner:MEREO BIOPHARMA 5 INC
Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
InactiveUS20050053579A1Reducing tumorigenicityPeptide/protein ingredientsAntibody mimetics/scaffoldsInterferon alphaWilms' tumor
The present invention relates to an immuno-therapy conjugate which comprises A-c-B wherein: A and B are different and are compounds selected from the group consisting of cytokines, chemokines, interferons, their respective receptors or a functional fragment thereof; and c is a linker consisting of a bond or an amino acid sequence containing from 1 to 100 residues. The present invention also relates to a vaccine adjuvant comprising the immuno-therapy conjugate of the present invention. The present invention further relates to a method of reducing tumor growth, for inhibiting a viral infection and for improving immune response in a patient.
Owner:GALIPEAU JACQUES +1
Rho-kinase inhibitors
Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
Owner:BAYER SCHERING PHARMA AG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com